1217237-98-3

Basic information

• Product Name: (E/Z)-N,N-Didesmethyl-4-hydroxy Tamoxifen
• Synonyms: (E/Z)-N,N-Didesmethyl-4-hydroxy Tamoxifen;4-[1-[4-(2-AMinoethoxy)phenyl]-2-phenyl-1-buten-1-yl]phenol
• CAS NO: 1217237-98-3
• Molecular Formula: C₂₄H₂₅NO₂
• Molecular Weight: 359.4608
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 1217237-98-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 185-192°C
• Appearance: /
• Storage Temp.: -20?C Freezer
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: (E/Z)-N,N-Didesmethyl-4-hydroxy Tamoxifen(CAS DataBase Reference)
• NIST Chemistry Reference: (E/Z)-N,N-Didesmethyl-4-hydroxy Tamoxifen(1217237-98-3)
• EPA Substance Registry System: (E/Z)-N,N-Didesmethyl-4-hydroxy Tamoxifen(1217237-98-3)

Safety Data

• Hazardous Substances Data: 1217237-98-3(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

A metabolite of Tamoxifen.

Upstream product

• 147323-02-2 E/Z-1-[4-(2-bromoethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbutene 
• 79578-62-4 (4-(2-bromoethoxy)phenyl)(4-hydroxyphenyl)methanone 
• 611-99-4 4,4'-Dihydroxybenzophenone 
• 91221-46-4 1,1-bis(4-hydroxyphenyl)-2-phenyl-1-butene 
• 32770-66-4 1-(1-phenylpropylidene)hydrazine 
• 93-55-0 1-phenyl-propan-1-one 
• 144108-80-5 1-(1,1-dibromobut-1-en-2-yl)benzene 

Downstream Products

• 1394929-55-5 (E)-4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-enyl)phenol 

Relevant articles and documents

NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF

The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β

The design and synthesis of dual aromatase inhibitors/selective estrogen receptor modulators (AI/SERMs) is an attractive strategy for the discovery of new breast cancer therapeutic agents. Previous efforts led to the preparation of norendoxifen (4) deriva